A phase 2, randomized, vehicle and ketoconazole-controlled, evaluator-blinded, study to explore the efficacy, pharmacodynamics and safety of omiganan 1.75% topical gel BID in patients with mild to moderate facial seborrheic dermatitis. - Omiganan BID in patients with facial seborrheic dermatitis

Maruho Co., Ltd.0 个研究点目标入组 36 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•For enrollment of subjects the following criteria must be met:
•1. Male and female subjects with mild to moderate facial SD (IGA 2 or 3), *18
•years of age, inclusive. The health status is verified by absence of evidence
•of any clinical significant active or uncontrolled chronic disease other than
•SD following a detailed medical history, a complete physical examination
•including vital signs, 12-lead ECG, hematology, blood chemistry, virology and
•urinalysis;
•2. Confirmed SD diagnosis by dermatologist
•3. Significant facial SD affected area as judged by the investigator or
•medically qualified designee.
•4. Able to participate and willing to give written informed consent and to
•comply with the study restrictions;
•5. Willing to refrain from using other SD treatments in the local treatment area
•6. Subjects and their partners of childbearing potential must use effective
•contraception, for the duration of the study and for 3 months after the last

•Eligible subjects must meet none of the following exclusion criteria:
•1. Any current and / or recurrent clinical significant skin condition other
•2. Ongoing use of prohibited SD medication. Washout periods prior to baseline
•are as follows;
•a. Topical steroids, antibiotics, antifungals or other (OTC) topical therapies:
•b. Systemic steroids, antibiotics, antifungals or other systemic therapies: 4
•c. Phototherapy: 3 weeks;
•d. Regular use of shampoo for the treatment of PC (including but not limited to
•OTC zinc pyrithione shampoo), soap for the treatment of seborrheic dermatitis:
•e. Changing a soap, method for daily facial and hair washing: 1 week
•3. Known hypersensitivity to the compounds or excipients of the compounds;
•4. Tanning due to sunbathing, excessive sun exposure or a tanning booth within
•3 weeks of enrollment;
•5. Pregnant, a positive pregnancy test, intending to become pregnant, or
•breastfeeding;
•6. Participation in an investigational drug or device study within 3 months
•prior to screening or more than 4 times in the past year;
•7. Loss or donation of blood over 500 mL within three months (males) or four
•months (females) prior to screening.

发起方